Skip to content

Eli Lilly LLY Debt Issuance Proceeds

Debt Issuance Proceeds at other companies

Amgen logo
AmgenAMGN
$3.96B
McKesson logo
McKessonMCK
$1.99B
AbbVie logo
AbbVieABBV
$7.99B+100%
Cencora logo
CencoraCOR

Other financials

Income statement

See full
Revenue$19.8B+55.5%
Gross profit$16.2B+54.4%
Net income$7.4B+168%
EPS (diluted)$8.26+170%

Balance sheet

See full
Cash & equivalents$5.3B+70.8%
Total debt$43.4B+12.6%
Total equity$31.2B+97.9%
Total assets$116.58B+30.4%

Cash flow

See full
Operating cash flow$5.3B+220%
CapEx$2.3B+54.0%
Free cash flow$3.0B+1,828%

Valuation

See full
Market cap$1.08T+54.2%
Enterprise value$1.12T+51.7%
P/E42.6×-8.0×
P/S14.9×+1.8×

Profitability

See full
Gross margin82.8%+1.1pp
Net margin35%+12.3pp
FCF margin16.4%+8.7pp

Returns & leverage

See full
Return on equity107.6%+29.9pp
Debt / equity1.4×-1.1×
Current ratio1.5×+0.1×

Where this comes from

Reported directly by Eli Lilly in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfLongTermDebt.

The official record: Eli Lilly’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Eli Lilly's debt issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Eli Lilly's debt issuance proceeds?
Eli Lilly (LLY) reported debt issuance proceeds of $0 in Q1 2026.
How has Eli Lilly's debt issuance proceeds changed year-over-year?
Eli Lilly's debt issuance proceeds decreased by 100.0% year-over-year, from $6.46B to $0.
What does debt issuance proceeds mean?
Cash received from issuing bonds, notes, term loans, and other debt instruments in the capital markets or from bank lending.